Wataru Kamata

Kamakura, 2470072, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemia.

Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemia.

Journal: International journal of hematology

Published: September 25, 2025

Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty Score.

Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty Score.

Journal: Mediterranean journal of hematology and infectious diseases

Published: July 05, 2025

Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag

Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 05, 2025

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma.

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma.

Journal: International journal of hematology

Published: January 09, 2025

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

Journal: Blood research

Published: November 17, 2024

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.

Journal: Pharmaceutics

Published: October 23, 2024

From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B-Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution.

From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B-Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution.

Journal: EJHaem

Published: September 08, 2023

Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma.

Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma.

Journal: Annals of hematology

Published: December 18, 2022

Plasmablastic myeloma initially presented with ascites

Plasmablastic myeloma initially presented with ascites

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 07, 2022

Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata.

Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata.

Journal: Frontiers in medicine

Published: March 14, 2022

Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report.

Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report.

Journal: BMC nephrology

Published: February 18, 2022

Prognostic factors in light-chain cardiac amyloidosis: a retrospective analysis

Prognostic factors in light-chain cardiac amyloidosis: a retrospective analysis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: December 06, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026